Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Aster DM Quality Care's average EBITDA Per Share Growth Rate was 8.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -4.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -6.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 5.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aster DM Quality Care was 22.20% per year. The lowest was -17.90% per year. And the median was 10.50% per year.
Aster DM Quality Care (NSE:ASTERDM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aster DM Quality Care 3-Year EBITDA Growth Rate Related Terms
NSE:ASTERDM vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Aster DM Quality Care's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aster DM Quality Care 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Aster DM Quality Care's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aster DM Quality Care's 3-Year EBITDA Growth Rate falls into.
Aster DM Quality Care 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -4.50% mean?
Aster DM Quality Care (NSE:ASTERDM) has a 3-Year EBITDA Growth Rate of -4.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aster DM Quality Care and its competitors. According to the industry distribution chart, Aster DM Quality Care ranks #403 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 76.5%.
Is Aster DM Quality Care's 3-Year EBITDA Growth Rate too high?
Aster DM Quality Care's current 3-Year EBITDA Growth Rate is -4.50%. Based on the distribution chart, Aster DM Quality Care ranks #403 out of 527 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Aster DM Quality Care has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aster DM Quality Care's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Aster DM Quality Care ranks #403 out of 527 companies for 3-Year EBITDA Growth Rate. This places Aster DM Quality Care in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aster DM Quality Care and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aster DM Quality Care's current 3-Year EBITDA Growth Rate is -4.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aster DM Quality Care stock overvalued right now?
Based on GuruFocus' analysis, Aster DM Quality Care (NSE:ASTERDM) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹610.34, compared to a current price of ₹869.70 — trading 42.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -4.50%. Aster DM Quality Care's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aster DM Quality Care (NSE:ASTERDM), the current 3-Year EBITDA Growth Rate is -4.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aster DM Quality Care (NSE:ASTERDM) Overvalued in 2026?
Based on GuruFocus' analysis, Aster DM Quality Care stock appears to be overvalued.
The current stock price of ₹869.70 is trading 42.5% above its estimated GF Value™ of ₹610.34.
GuruFocus considers Aster DM Quality Care to be Significantly Overvalued.
Key valuation signals for NSE:ASTERDM:
3-Year EBITDA Growth Rate: -4.50%
GF Value™: ₹610.34 vs. price of ₹869.70 (42.5% above fair value)
No single metric tells the full story. See the NSE:ASTERDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aster DM Healthcare Ltd is an India-based integrated healthcare provider. The group operates a comprehensive healthcare network comprising approximately 19 hospitals, 10 clinics, over 200 pharmacies, and more than 255 diagnostic laboratories across states. Its business segments include Hospitals, Clinics, Retail Pharmacies, and Others, with the majority of revenue derived from the Hospitals segment. Aster has been delivering high-quality care from primary to quaternary through dedicated personnel across clinical and non-clinical roles. Aster has a presence in metropolitan as well as Tier II and Tier III cities, and is committed to providing advanced and accessible healthcare in line with global standards, guided by a patient-first approach.
69GF Score
Get the complete analysis for NSE:ASTERDM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTERDM has been successfully added to your 
